273 related articles for article (PubMed ID: 29776017)
1. Pharmacokinetics and C-reactive protein modelling of anti-interleukin-6 antibody (PF-04236921) in healthy volunteers and patients with autoimmune disease.
Li C; Shoji S; Beebe J
Br J Clin Pharmacol; 2018 Sep; 84(9):2059-2074. PubMed ID: 29776017
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis.
Ternant D; Ducourau E; Fuzibet P; Vignault C; Watier H; Lequerré T; Le Loët X; Vittecoq O; Goupille P; Mulleman D; Paintaud G
Br J Clin Pharmacol; 2015 Feb; 79(2):286-97. PubMed ID: 25223394
[TBL] [Abstract][Full Text] [Related]
3. A clinical population pharmacokinetic/pharmacodynamic model for BIIB059, a monoclonal antibody for the treatment of systemic and cutaneous lupus erythematosus.
Hartmann S; Biliouris K; Naik H; Rabah D; Stevenson L; Shen C; Nestorov IA; Lesko LJ; Trame MN
J Pharmacokinet Pharmacodyn; 2020 Jun; 47(3):255-266. PubMed ID: 32335844
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetics and Pharmacodynamics of Ontamalimab (SHP647), a Fully Human Monoclonal Antibody Against Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1), in Patients With Ulcerative Colitis or Crohn's Disease.
Wang Y; Marier JF; Lavigne J; Kassir N; Martin P
J Clin Pharmacol; 2020 Jul; 60(7):903-914. PubMed ID: 32119128
[TBL] [Abstract][Full Text] [Related]
5. A pharmacokinetic comparison of anrukinzumab, an anti- IL-13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patients.
Hua F; Ribbing J; Reinisch W; Cataldi F; Martin S
Br J Clin Pharmacol; 2015 Jul; 80(1):101-9. PubMed ID: 25614144
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study.
Xu Z; Bouman-Thio E; Comisar C; Frederick B; Van Hartingsveldt B; Marini JC; Davis HM; Zhou H
Br J Clin Pharmacol; 2011 Aug; 72(2):270-81. PubMed ID: 21392075
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, following single-dose administration by subcutaneous and intravenous routes to healthy subjects.
Zhang X; Georgy A; Rowell L
Int J Clin Pharmacol Ther; 2013 Jun; 51(6):443-55. PubMed ID: 23547848
[TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetics (PK) and Pharmacodynamics (PD) Analysis of LY3015014, a Monoclonal Antibody to Protein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Healthy Subjects and Hypercholesterolemia Patients.
Shen T; James DE; Krueger KA
Pharm Res; 2017 Jan; 34(1):185-192. PubMed ID: 27822850
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients.
Zheng B; Yu XQ; Greth W; Robbie GJ
Br J Clin Pharmacol; 2016 May; 81(5):918-28. PubMed ID: 26659791
[TBL] [Abstract][Full Text] [Related]
10. Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I-III Clinical Trials.
Suleiman AA; Minocha M; Khatri A; Pang Y; Othman AA
Clin Pharmacokinet; 2019 Oct; 58(10):1309-1321. PubMed ID: 31054118
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics and Pharmacodynamics Modelling of Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress Syndrome.
Yang S; Dumitrescu TP
Drugs R D; 2017 Mar; 17(1):145-158. PubMed ID: 28004376
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin
Chen X; Li C; Ewesuedo R; Yin D
Cancer Chemother Pharmacol; 2019 Jul; 84(1):83-92. PubMed ID: 31053945
[TBL] [Abstract][Full Text] [Related]
13. Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.
Diao L; Hang Y; Othman AA; Nestorov I; Tran JQ
Clin Pharmacokinet; 2016 Aug; 55(8):943-55. PubMed ID: 26873229
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease.
Rosario M; Dirks NL; Gastonguay MR; Fasanmade AA; Wyant T; Parikh A; Sandborn WJ; Feagan BG; Reinisch W; Fox I
Aliment Pharmacol Ther; 2015 Jul; 42(2):188-202. PubMed ID: 25996351
[TBL] [Abstract][Full Text] [Related]
15. Population Pharmacokinetics and Pharmacodynamics of Benralizumab in Healthy Volunteers and Patients With Asthma.
Wang B; Yan L; Yao Z; Roskos LK
CPT Pharmacometrics Syst Pharmacol; 2017 Apr; 6(4):249-257. PubMed ID: 28109128
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus.
Narwal R; Roskos LK; Robbie GJ
Clin Pharmacokinet; 2013 Nov; 52(11):1017-27. PubMed ID: 23754736
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetics of Galcanezumab, an Anti-CGRP Antibody, Following Subcutaneous Dosing to Healthy Individuals and Patients With Migraine.
Kielbasa W; Quinlan T
J Clin Pharmacol; 2020 Feb; 60(2):229-239. PubMed ID: 31482569
[TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials.
Suleiman AA; Khatri A; Minocha M; Othman AA
Clin Pharmacokinet; 2019 Mar; 58(3):375-387. PubMed ID: 30123942
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetics Study of Contezolid (MRX-I), a Novel Oxazolidinone Antibacterial Agent, in Chinese Patients.
Li L; Wu H; Chen Y; Yuan H; Wu J; Wu X; Zhang Y; Cao G; Guo B; Wu J; Zhao M; Zhang J
Clin Ther; 2020 May; 42(5):818-829. PubMed ID: 32389326
[TBL] [Abstract][Full Text] [Related]
20. Population Pharmacokinetic/Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen-Induced Platelet Aggregation.
Renaud L; Lebozec K; Voors-Pette C; Dogterom P; Billiald P; Jandrot Perrus M; Pletan Y; Machacek M
J Clin Pharmacol; 2020 Sep; 60(9):1198-1208. PubMed ID: 32500636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
